Korean Society of Clinical Hypertension Discusses Latest Treatment Strategies for Cerebrovascular Diseases and Dyslipidemia

by Hyeon Mi Cho Posted : October 29, 2026, 20:40Updated : October 29, 2026, 20:40

The Korean Society of Clinical Hypertension announced on the 29th that it held a symposium on the latest treatment strategies for cerebrovascular diseases and complex dyslipidemia in collaboration with Korean United Pharmaceutical on the 27th at Signiel Seoul in Songpa-gu, Seoul.


The symposium covered the latest clinical evidence on antiplatelet therapy for cerebrovascular diseases and treatment for complex dyslipidemia, including the clinical significance of cilostazol and statin/omega-3 combination therapies.


Professor Park Kwang-yeol from Chung-Ang University’s Department of Neurology presented on “Optimal Antiplatelet Therapy and Latest Insights on Cilostazol for Cerebrovascular Management,” while Professor Bae Sung-ah from Yonsei University’s Department of Cardiology discussed “Treatment Strategies for Complex Dyslipidemia: New Formulation of Statin + Omega-3.”


During the subsequent discussion, participants addressed issues regarding the reduction of specimen testing prices and the accuracy of low-density lipoprotein cholesterol (LDL-C) measurements.


Lee Hyuk, president of the Korean Society of Clinical Hypertension, stated, “Hypertension, dyslipidemia, and cerebrovascular diseases are conditions we encounter daily in primary care, so evidence-based personalized treatment must be quickly established in outpatient settings.”


He also emphasized that “the targets of LDL-C below 70 mg/dL and triglycerides below 150 mg/dL are no longer options but standards,” adding that “when it comes to omega-3, selecting a dosage that balances efficacy and safety is crucial rather than just opting for high doses.”


Meanwhile, the Korean Society of Clinical Hypertension will hold its autumn academic conference on November 15 at the Kim Dae-jung Convention Center in Seo-gu, Gwangju. The conference will address significant changes in domestic and international hypertension treatment guidelines and personalized treatment strategies for elderly hypertension patients, focusing on topics applicable in primary care settings.





* This article has been translated by AI.